Details
Stereochemistry | ACHIRAL |
Molecular Formula | C27H30F2N2O3.2ClH |
Molecular Weight | 541.457 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.COC1=CC=C(CN2CCN(CC2)C(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)C(OC)=C1OC
InChI
InChIKey=LOGVKVSFYBBUAJ-UHFFFAOYSA-N
InChI=1S/C27H30F2N2O3.2ClH/c1-32-24-13-8-21(26(33-2)27(24)34-3)18-30-14-16-31(17-15-30)25(19-4-9-22(28)10-5-19)20-6-11-23(29)12-7-20;;/h4-13,25H,14-18H2,1-3H3;2*1H
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/24074550Curator's Comment: description was created based on several sources, including:
http://www.alomone.com/p/lomerizine_dihydrochloride_/l-125/7
http://www.ncbi.nlm.nih.gov/pubmed/15492768
Sources: http://www.ncbi.nlm.nih.gov/pubmed/24074550
Curator's Comment: description was created based on several sources, including:
http://www.alomone.com/p/lomerizine_dihydrochloride_/l-125/7
http://www.ncbi.nlm.nih.gov/pubmed/15492768
Lomerizine (INN) (also known as KB-2796) is a diphenylpiperazine class L-type and T-type calcium channel blocker with relatively selective CNS effects. Voltage dependent L-type Ca2+ channels play an important role Ca2+ influx. L-type calcium currents typically require a strong depolarization for activation and are long-lasting. The common pharmacological profile of L-type channels is determined by the α1 subunit, which forms the Ca2+ selective. Lomerizine was developed as a potential agent for the selective improvement of the ocular or cerebrovascular circulation with minimal adverse cardiovascular effects, and it is used as an anti- migraine drug. Lomerizine selectively relaxes smooth muscle cells by inhibiting L-type Ca2+ influx, thereby reducing tone and increasing blood flow in cerebral vessels. Lomerizine also shows neuroprotective effects against secondary degeneration resulting from injury in retinal ganglion cells. While some calcium-channel blockers, such as flunarizine, act on the dopaminergic system, lomerizine is ineffective in vivo at inhibiting the release of dopamine. However, it has been observed to weakly inhibit the binding of [3H]spiperone to D2 dopamine receptors in vitro. While researchers are unsure of the reason for this difference, one hypothesis is that the doses administered cannot reach a high enough concentration in the brain to affect D2 receptors.
Originator
Sources: http://adisinsight.springer.com/drugs/800002033
Curator's Comment: # Nippon Organon; Pfizer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095229 |
|||
Target ID: CHEMBL2362995 Sources: http://www.ncbi.nlm.nih.gov/pubmed/21112351 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Clinical potential of lomerizine, a Ca2+ channel blocker as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. | 2004 Fall |
|
[Prophylactic treatment of migraine]. | 2005 Oct |
|
[Migraine improved by amlodipine medication in a case with hypertension]. | 2008 Sep |
|
Scaffold-based design and synthesis of potent N-type calcium channel blockers. | 2009 Nov 15 |
|
[New developments in glaucoma medical treatment]. | 2009 Oct |
|
Lomerizine, a Ca2+ channel blocker, protects against neuronal degeneration within the visual center of the brain after retinal damage in mice. | 2010 Apr |
|
Early events of secondary degeneration after partial optic nerve transection: an immunohistochemical study. | 2010 Feb |
|
Interaction of CJZ3, a lomerizine derivative, with ATPase activity of human P-glycoprotein in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. | 2010 Jul |
|
Limited restoration of visual function after partial optic nerve injury; a time course study using the calcium channel blocker lomerizine. | 2010 Mar 16 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/14578410
Oral 5 mg lomerizine or placebo was administered to volunteers (n=8) in a crossover study
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/8076888
In rat cortical membrane, KB-2796 (LOMERIZINE) inhibited specific [3H]spiperone binding to 5-HT2 receptors in a competitive manner (Ki = 0.57 uM), but exhibited negligible affinity for radioligand binding to other 5-HT receptor subtypes such as 5-HT1, 5-HT1A, 5-HT1B, 5-HT1C and 5-HT3 at a concentration of 10 or 100 uM. KB-2796 also inhibited the 5-HT-induced increase of [Ca2+]i in washed rabbit platelets with the IC50 value of 25.7 uM
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3W473D5LIY
Created by
admin on Fri Dec 15 17:12:40 GMT 2023 , Edited by admin on Fri Dec 15 17:12:40 GMT 2023
|
PRIMARY | |||
|
DBSALT002715
Created by
admin on Fri Dec 15 17:12:40 GMT 2023 , Edited by admin on Fri Dec 15 17:12:40 GMT 2023
|
PRIMARY | |||
|
100000085664
Created by
admin on Fri Dec 15 17:12:40 GMT 2023 , Edited by admin on Fri Dec 15 17:12:40 GMT 2023
|
PRIMARY | |||
|
m6890
Created by
admin on Fri Dec 15 17:12:40 GMT 2023 , Edited by admin on Fri Dec 15 17:12:40 GMT 2023
|
PRIMARY | Merck Index | ||
|
C052424
Created by
admin on Fri Dec 15 17:12:40 GMT 2023 , Edited by admin on Fri Dec 15 17:12:40 GMT 2023
|
PRIMARY | |||
|
DTXSID1046427
Created by
admin on Fri Dec 15 17:12:40 GMT 2023 , Edited by admin on Fri Dec 15 17:12:40 GMT 2023
|
PRIMARY | |||
|
101477-54-7
Created by
admin on Fri Dec 15 17:12:40 GMT 2023 , Edited by admin on Fri Dec 15 17:12:40 GMT 2023
|
PRIMARY | |||
|
122125
Created by
admin on Fri Dec 15 17:12:40 GMT 2023 , Edited by admin on Fri Dec 15 17:12:40 GMT 2023
|
PRIMARY | |||
|
SUB21430
Created by
admin on Fri Dec 15 17:12:40 GMT 2023 , Edited by admin on Fri Dec 15 17:12:40 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD